With 1.34 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.85 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $13.53 whereas the lowest price it dropped to was $12.71. The 52-week range on NAGE shows that it touched its highest point at $13.11 and its lowest point at $2.31 during that stretch. It currently has a 1-year price target of $14.90. Beta for the stock currently stands at 2.09.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NAGE was up-trending over the past week, with a rise of 14.49%, but this was up by 45.35% over a month. Three-month performance surged to 70.43% while six-month performance rose 78.35%. The stock gained 369.58% in the past year, while it has gained 153.16% so far this year. A look at the trailing 12-month EPS for NAGE yields 0.17 with Next year EPS estimates of 0.24. For the next quarter, that number is 0.01. This implies an EPS growth rate of 25.10% for this year and 74.08% for next year.
Float and Shares Shorts:
At present, 78.43 million NAGE shares are outstanding with a float of 49.81 million shares on hand for trading. On 2025-05-15, short shares totaled 2.2 million, which was 279.0 higher than short shares on 1744675200. In addition to Mr. Frank Louis Jaksch Jr. as the firm’s Co-Founder & Chairman, Mr. Robert N. Fried serves as its CEO & Director.
Institutional Ownership:
Through their ownership of 0.32928002 of NAGE’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, NAGE reported revenue of $30481000.0 and operating income of $4772000.0. The EBITDA in the recently reported quarter was $5140000.0 and diluted EPS was $0.06.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With NAGE analysts setting a high price target of 23.0 and a low target of 9.6, the average target price over the next 12 months is 14.15. Based on these targets, NAGE could surge 71.26% to reach the target high and fall by -28.52% to reach the target low. Reaching the average price target will result in a growth of 5.36% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0.0405497 being high and $0.0392151 being low. For NAGE, this leads to a yearly average estimate of $0.04.
